 | |
- close
- close
|
Marketwire
Sep 29
Comment
SYDNEY, AUSTRALIA and NEW CANAAN, CT -- (Marketwire) -- 09/29/09 -- Marshall Edwards, Inc. (NASDAQ: MSHL), a pharmaceutical company specializing in clinical development of oncology drugs, today released data demonstrating that the efficacy of NV-128
Marketwire
Sep 22
Comment
NEW CANAAN, CT -- (Marketwire) -- 09/22/09 -- Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that on September 16, 2009, as management
Marketwire
Aug 5
Comment
NEW CANAAN, CT and SYDNEY, AUSTRALIA -- (Marketwire) -- 08/05/09 -- Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have concluded a license agreement for Marshall Edwards to develop and commercialize the oncology
Marketwire
Jul 30
Comment
SYDNEY, AUSTRALIA -- (Marketwire) -- 07/30/09 -- The Board of Novogen Limited (ASX: NRT) (NASDAQ: NVGN) has received and accepted the resignation of Mr. Peter B. Simpson as a Director of the Company. Mr. Simpson has been the longest serving Director
Marketwire
Jul 7
Comment
NEW CANAAN, CT and SYDNEY, AUSTRALIA -- (Marketwire) -- 07/07/09 -- Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand have found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as
Marketwire
Jun 17
Comment
NEW CANAAN, CT -- (Marketwire) -- 06/17/09 -- The Independent Data Monitoring Committee (IDMC) created to oversee the conduct of the Phase III OVArian TUmor REsponse (OVATURE) Trial, which convened during the recent Annual Meeting of the American
TheStreet.com
May 20
Comment
Itty bitty biotechs are big again, thanks to the H1N1 virus, cancer drug abstracts, and Vanda's recent success.
Marketwire
Apr 20
Comment
NEW CANAAN, CT and SYDNEY, AUSTRALIA -- (Marketwire) -- 04/20/09 -- Data presented yesterday at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that NV-128, a Novogen, Limited (ASX: NRT) (NASDAQ: NVGN)
Marketwire
Apr 14
Comment
NEW CANAAN, CT and SYDNEY, AUSTRALIA -- (Marketwire) -- 04/14/09 -- Marshall Edwards, Inc., (NASDAQ: MSHL) today announced that it will be undertaking an un-blinded analysis of the data from its Phase III international, multicenter clinical study
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
NVGN AT A GLANCE
References
| ||||||
|
|
